Invivyd Inc

Invivyd Inc

IVVD

Get informed when a big investor buys or sells

+ Follow
Market Cap$151.31M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Invivyd IncInvivyd Inc-4.5--38%--
$4.30

Current Fair Value

291.4% upside

Undervalued by 291.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$151.31 Million
Enterprise Value$-24,215,436.00
Dividend Yield$- (-)
Earnings per Share$-0.3
Beta0.71
Outstanding Shares309,670,101

Return

Return on Equity-38.22%ROE
Return on Assets-32.10%
Return on Invested Capital-39.13%

Valuation & Multiples

P/E Ratio-4.55P/E Ratio
PEG-2.95PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-0.43
Enterprise Value to EBIT0.29
Enterprise Value to Net Income0
Total Debt to Enterprise-0.36
Debt to Equity0.04Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 21, 2026
EPS Estimate
$-0.08
Average shareholder expectation
Revenue Estimate
$18.04 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 13, 2026
EPS Estimate
$-0.15
Average shareholder expectation
Revenue Estimate
$14.40 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.3663 22.50%
Total Calls561,000 19.97%
Total Puts205,500 50.42%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %131.50% 9.63%
Total Invested$294.24M 50.44%
Investors Holding146 25.00%

ESG Score

No data

About Invivyd Inc

2,021 employees

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antib...